Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy.

Tae-Hyung KimSoon Ho UmYoung-Sun LeeSun Young YimYoung Kul JungYeon Seok SeoJi Hoon KimHyunggin AnHyung Joon YimJong Eun YeonKwan Soo Byun

Published in: Alimentary pharmacology & therapeutics (2021)

Six clinical parameters, including AFP and the timing of antiviral therapy, were combined into a scoring system to accurately predict early re-compensation in patients with HBV-related decompensated cirrhosis.

Keyphrases

hepatitis b virus
liver failure
heart failure
stem cells
bone marrow
mesenchymal stem cells
cell therapy